概述

当癌细胞从原来的位置扩散到大脑时,就会引起脑转移瘤。任何癌症都可以扩散到大脑,但最容易引起脑转移瘤的类型是肺癌、乳腺癌、结肠癌、肾癌和黑色素瘤。

脑转移瘤可在脑内形成一个或多个肿瘤。转移性脑肿瘤逐渐生长,对周围脑组织产生压力并改变其功能。这会引起各种体征和症状,如头痛、性格变化、记忆丧失和癫痫发作。

对于癌症扩散到脑部的患者,治疗可能包括手术、放射疗法、化疗、免疫疗法或这些方法的组合。在某些情况下,可能建议接受其他治疗。治疗的重点通常是减轻疼痛和癌症引起的症状。

症状

由脑转移瘤引起的体征和症状可能因转移瘤的位置、大小和生长速度而异。

脑转移瘤的体征和症状包括:

  • 头痛,有时伴有呕吐或恶心
  • 精神变化,例如记忆力问题渐增
  • 癫痫发作
  • 单侧身体无力或麻木

何时就诊

如果出现令您担心的持续体征或症状,请与医生约诊。如果您曾经接受过癌症治疗,请将您的病史告知医生。

病因

当癌细胞从原发位置扩散时,就会引起脑转移瘤。癌细胞可能通过血流或淋巴系统扩散(转移)到脑部,并在此开始增殖。

从原发位置扩散的转移性癌症根据原发性癌症命名。例如,从乳房扩散到脑部的癌症称为转移性乳腺癌,而不是脑癌。

风险因素

任何类型的癌症都可能扩散到大脑,但是某些类型的癌症引起脑转移瘤的风险更高,包括:

  • 肺癌
  • 乳腺癌
  • 结肠癌
  • 肾癌
  • 黑色素瘤

Nov. 20, 2024
  1. Shih HA. Epidemiology, clinical manifestations, and diagnosis of brain metastases. https://www.uptodate.com/contents/search. Accessed March. 22, 2024.
  2. Niederhuber JE, et al., eds. Brain metastases and neoplastic meningitis. In: Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Sept. 23, 2020.
  3. Shih HA. Overview of the treatment of brain metastases. https://www.uptodate.com/contents/search. Accessed March 22, 2024.
  4. Metastatic cancer. National Cancer Institute. https://www.cancer.gov/types/metastatic-cancer. Accessed March 13, 2024.
  5. Central nervous system cancers. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed March 15, 2024.
  6. Ask Mayo Expert. Brain metastases (adult). Mayo Clinic; 2024.
  7. Treatments and side effects. American Brain Tumor Association. https://www.abta.org/about-brain-tumors/treatments-side-effects/. Accessed March 19, 2024.
  8. Brondfield S, et al. Developing a community for patients with cancer through longer-term art therapy. Oncology Practice. 2020; doi:10.1200/OP.20.00419.
  9. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Jan. 3, 2024.
  10. Coping with cancer. Cancer.Net. https://www.cancer.net/coping-with-cancer. Accessed Jan. 4, 2024.
  11. Le Rhun E, et al. Leptomeningeal metastases of solid cancer. Current Opinion in Neurology. 2016; doi:10.1097/WCO.0000000000000393.
  12. Rades D, et al. A new scoring tool to assess overall survival in patients with intracerebral metastases from gynecological cancers. International Journal of Gynecological Cancer. 2017; doi:10.1097/IGC.0000000000000899.
  13. Klos KJ, et al. Brain metastases. The Neurologist. 2004; doi:10.1097/01.nrl.0000106922.83090.71.
  14. Heim JB, et al. Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Proceedings of the National Academy of Sciences of the United States of America. 2017; doi:10.1073/pnas.1614894114.
  15. O'Neill BP, et al. Brain metastatic lesions. Mayo Clinic Proceedings. 1994; doi:10.1016/S0025-6196(12)61374-3.
  16. Brown PD, et al. Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases. JAMA. 2016; doi:10.1001/jama.2016.9839.
  17. Brown PD, et al. NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Journal of Clinical Oncology. 2015; doi:10.1200/jco.2015.33.18_suppl.lba4.
  18. Rades D, et al. A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. BMC Cancer. 2017; doi:10.1186/s12885-016-2989-3.
  19. Rades D, et al. Prognostic factors after whole-brain radiotherapy alone for brain metastases from malignant melanoma. Anticancer Research. 2016; doi:10.21873/anticanres.11271.
  20. Crozier JA, et al. Breast cancer brain metastases: Molecular subtype, treatment and survival. Breast Disease. 2016; doi:10.3233/BD-160237.
  21. Cheville AL, et al. Nested cohort study to identify characteristics that predict near-term disablement from lung cancer brain metastases. Archives of Physical Medicine and Rehabilitation. 2017; doi:10.1016/j.apmr.2016.08.473.